Immune Pharmaceuticals (NASDAQ: IMNP) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.
This is a breakdown of current recommendations and price targets for Immune Pharmaceuticals and Pfizer, as reported by MarketBeat.com.
||Strong Buy Ratings
Immune Pharmaceuticals currently has a consensus target price of $3.00, indicating a potential upside of 455.56%. Pfizer has a consensus target price of $39.29, indicating a potential upside of 13.53%. Given Immune Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Immune Pharmaceuticals is more favorable than Pfizer.
Pfizer pays an annual dividend of $1.36 per share and has a dividend yield of 3.9%. Immune Pharmaceuticals does not pay a dividend. Pfizer pays out 38.6% of its earnings in the form of a dividend. Pfizer has raised its dividend for 8 consecutive years.
Volatility and Risk
Immune Pharmaceuticals has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
Insider & Institutional Ownership
1.6% of Immune Pharmaceuticals shares are held by institutional investors. Comparatively, 70.1% of Pfizer shares are held by institutional investors. 3.9% of Immune Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Immune Pharmaceuticals and Pfizer’s top-line revenue, earnings per share and valuation.
||Earnings Per Share
Pfizer has higher revenue and earnings than Immune Pharmaceuticals. Immune Pharmaceuticals is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.
This table compares Immune Pharmaceuticals and Pfizer’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Pfizer beats Immune Pharmaceuticals on 11 of the 16 factors compared between the two stocks.
About Immune Pharmaceuticals
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.